Navigation Links
Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
Date:9/2/2010

rmaceutical Technology". Professor Leroux is an expert in galenic studies from the Swiss Federal Institute of Technology (ETH) in Zurich. He and his institute received CHF 100'000. Funded by Debiopharm, the ceremony took place at the EPFL (Ecole Polytechnique Federale de Lausanne) during the EPFL School of Life Sciences Symposium entitled "Engineering Life".

"We congratulate Professor Leroux for his outstanding research," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group(TM). "A panel of experts from Debiopharm and the EPFL examined many high-level and promising applications from all over Europe; our decision to nominate Professor Leroux was unanimous. We were seduced by his innovative research, his general expertise and broad overall knowledge in drug delivery. The application file submitted by Professor Leroux was very comprehensive, with an impressive list of publications in high-impact factor pharmaceutical, materials and biomedical journals. He is a leading figure in an area that is likely to revolutionise medical therapeutics in the years to come."

The development of suitable drug formulations and delivery systems remains a major challenge in the full drug product development and industrialisation process. In his applied research, Professor Leroux is interested in the design of new carriers and materials for various pharmaceutical applications such as drug detoxification and the treatment of celiac disease (intolerance to gluten). Currently different approaches are being assessed as a supportive treatment of celiac disease. The polymeric binder technology which was developed in his laboratory will be further investigated. In parallel, he will examine another known strategy to study the stability of enzymes (exogenous propyl endopeptidases) in the gastro intestinal tract and try to improve it with various new polymers. He will also elaborate imaging tools to study in real time the enzymatic activity in vivo. Professor Leroux
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Professor-turned-producer learns the movie biz
2. UCF professor develops vaccine to protect against black plague bioterror attack
3. Stuart Parkin first distinguished professor at Eindhoven University of Technology
4. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
5. UCF professor develops vaccine to protect against black plague bioterror attack
6. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
7. Gift Aids Professor's Research into Vein Treatment
8. Thin films research lands engineering professor Air Force Young Investigator Award
9. Nyenrode Honorary Doctorate for Professor Michael E. Porter
10. Professor K. C. Nicolaou Speaks at WuXi AppTec
11. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes, Jr. Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... ROCKVILLE, Md. , April 16, 2015 /PRNewswire/ ... "RegeneRx") today announced its U.S. joint venture with ... conduct a phase 3 clinical trial for the ... dose-response, confirmatory trial for dry eye syndrome (DES) ... ReGenTree,s preservative-free eye drops, RGN-259/GBT201, this year.  Each ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... April 16, 2015 Avelas Biosciences, an ... cancer surgeries, announced today that it has initiated a ... AVB-620, in women with primary, non-recurrent breast cancer undergoing ... welcomed the addition of Steven Chen , M.D., ... open label, dose escalation study will enroll up to ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... 2011   Elsevier, the leading ... will present awards to outstanding members of the wilderness medicine ... Wilderness Medicine Scientific Conference & Annual Meeting , taking place ... rd . The aim of the Wilderness Medicine ...
... Switzerland and RALEIGH, North Carolina, July 26, 2011 ... a therapeutically focused contract research organisation (CRO) with ... Debiopharm Group™ ("Debiopharm"), a Swiss-based global biopharmaceutical group ... diagnostics, today announced a strategic partnership. Under the ...
... 25, 2011 Rising star Divine Skin Inc. (DSKX), which ... Robin Powell, a long-time leader in the cosmetics industry, to ... of retirement by Divine Skin because I believe their innovative ... give proven results with a ,wow, factor." ...
Cached Biology Technology:Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 2Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 3INC Research and Debiopharm Group(TM) Announce Strategic Partnership 2INC Research and Debiopharm Group(TM) Announce Strategic Partnership 3Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... New research from the University of Michigan Comprehensive ... protein that fuels an inflammatory pathway does not turn ... cancer stem cells. This provides a potential target for ... of the disease. The researchers identified a protein, ...
... glioblastoma cancers so difficult to treat is that malignant cells ... fibers and blood vessels to invade new locations. Now, researchers ... the cancer by using a film of nanofibers thinner than ... of invading new areas, the migrating cells latch onto the ...
... life on earth, is also its least explored environment. ... the ocean,s deep regions, exploiting the deep,s resources and ... for the planet at risk. Lisa Levin, a ... San Diego, believes the vital functions provided by the ...
Cached Biology News:New finding points to potential options for attacking stem cells in triple-negative breast cancer 2Researchers hijack cancer migration mechanism to 'move' brain tumors 2Researchers hijack cancer migration mechanism to 'move' brain tumors 3Researchers hijack cancer migration mechanism to 'move' brain tumors 4Scientists call for new stewardship of the deep ocean: Earth's last frontier 2Scientists call for new stewardship of the deep ocean: Earth's last frontier 3
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
Contains L-glutamine...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: